title: Severe vernal keratoconjunctivitis successfully treated with subcutaneous omalizumab.
abstract: A 12-year-old boy with severe mixed limbal and palpebral vernal keratoconjunctivitis experienced persistent ocular symptoms despite treatment with topical corticosteroids or cyclosporine. Signs and symptoms resolved completely with monthly subcutaneous omalizumab, an immunomodulating biologic agent. To our knowledge, this is the first report of its use as a monotherapy agent to treat vernal keratoconjunctivitis.
authors.affiliation: Manchester Royal Eye Hospital, Manchester, United Kingdom. timothydeklerk@yahoo.com
authors.forename: Timothy A
authors.initials: TA
authors.lastname: de Klerk
authors.forename: Vibha
authors.initials: V
authors.lastname: Sharma
authors.forename: Peter D
authors.initials: PD
authors.lastname: Arkwright
authors.forename: Susmito
authors.initials: S
authors.lastname: Biswas
mesh_terms: D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D002648:Child; D003233:Conjunctivitis, Allergic / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D000069444:Omalizumab; D016896:Treatment Outcome; D014792:Visual Acuity
chemical_list: D018926:Anti-Allergic Agents; D000888:Antibodies, Anti-Idiotypic; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab